Jump to navigation

Mobile menu button
ILD Collaborative logo
  • About
  • Partner Centers
  • People
  • Project ECHO for ILD
    • 2022-2023 Curriculum
      • Idiopathic Pulmonary Fibrosis: A Diagnostic Approach
      • Shifting Paradigms of IPF Pathogenesis
      • Treatments for Idiopathic Pulmonary Fibrosis
      • Overview of Autoimmune ILD
      • Scleroderma-Associated ILD: Clinical Manifestations and Diagnosis
      • Idiopathic Pulmonary Fibrosis: Natural History and Survival
      • Myositis-Associated ILD: Clinical Manifestations and Diagnosis
      • Lung Biopsy in the Diagnosis of Fibrotic ILD
      • Sarcoidosis: Overview, Diagnosis and Monitoring
      • Rethinking Classification Criteria for Connective Tissue Diseases
      • Post-acute Sequelae of COVID-19 (PASC)
      • Acute Exacerbations of ILD
      • Scleroderma-Associated ILD: Treatment Approaches and Challenges
      • Myositis-Associated ILD: Treatment Approaches and Challenges
      • Pulmonary Hypertension Associated with ILD
      • More Than Meds: Nonpharmacologic Treatments for ILD
      • Hypersensitivity Pneumonitis: Approach and Challenges
      • Lung Transplant for ILD: When to Refer and What to Expect
      • Sarcoidosis: Beyond First Line Therapy
      • Genetics and the Development of Pulmonary Fibrosis
      • Hypersensitivity Pneumonitis: Treatment Approach and Challenges
      • HRCT Patterns and Pitfalls: Approach to Fibrotic Lung Disease
      • Common Comorbidities of ILD
      • Quality of Life and ILD: Palliative Care Along the Trajectory of Illness
    • 2024-2025 Curriculum
      • Rheumatoid Arthritis-Associated ILD
      • Shifting Paradigms of IPF Pathogenesis
      • HRCT Patterns and Pitfalls: Approach to Fibrotic Lung Disease
      • Myositis-Associated ILD: Clinical Manifestations and Diagnosis
      • Emerging Treatments for Pulmonary Fibrosis and Active Clinical Trials
      • Lung Cancer in Patients with ILD: Diagnostic and Management Considerations
      • Rethinking Classification Criteria for Connective Tissue Diseases
      • A Guide to Immunosuppression
      • Lung Biopsy in the Diagnosis of ILD
      • Hypersensitivity Pneumonitis: Diagnostic Approach and Challenges
      • ANCA-associated ILD
      • Acute Exacerbations of ILD
      • Scleroderma-Associated ILD: Treatment Approaches and Challenges
      • Pulmonary Complications of Immunotherapy
      • Post-acute Sequelae of COVID-19 (PASC): “Long-haulers” and Pulmonary Disease
      • Hypersensitivity Pneumonitis: Update on Treatment Approaches
      • Pulmonary Hypertension Associated with ILD: Diagnosis and Management
      • Occupational Lung Disease
      • Myositis-Associated ILD: Treatment Approaches and Challenges
      • Lung Transplant for ILD: When to Refer and What to Expect
      • Obliterative Bronchiolitis
      • Sarcoidosis: Conventional and Evolving Treatments
      • Quality of Life and ILD: The Role of Palliative Care
      • Genetics and the Development of Pulmonary Fibrosis
      • Common Comorbidities of ILD
    • Project ECHO for ILD
    • Registration
      • Unsubscribe from Project ECHO for ILD
  • Virtual Meetings
    • Air Filtration
    • Air Pollution and Interstitial Lung Disease
    • Airway Clearance
    • Anesthesia for People With Interstitial Lung Disease
    • Art Therapy in Chronic Illness
    • Cough in ILD: Its Causes and Management
    • Eight Active Ingredients of Tai Chi
    • Gastroesophageal Reflux Disease (GERD) and ILD
    • Hypersensitivity Pneumonitis
    • Immunomodulatory Agents in the Treatment of ILD
    • Implementing Energy Conservation Strategies
    • Interstitial Lung Disease: The Journey to Diagnosis and Treatment
    • Living Better with ILD
    • Lung Transplant: Eligibility and Evaluation
    • Monthly Oxygen Therapy Series: Is It Time to Use Oxygen?
    • Monthly Oxygen Therapy Series: Portable Oxygen Concentrators and Travel
    • Monthly Palliative Care Series: Palliative Care and QoL in ILD
    • Nutritional Considerations for ILD
    • Pranayama: The Art and Science of Slow Breathing
    • Pulmonary Hypertension: Diagnosis and Management
    • Sarcoidosis: Is There Better Treatment?
    • The Lived Experience Series: Financial and Tax Planning
    • The Role of Ablation for Lung Cancer Treatment in ILD
    • Understanding Autoimmune-Related ILD
    • Unsubscribe from our Mailing Lists
    • Updates on Clinical Research for IPF and Other Forms of ILD (2023)
    • Updates on Clinical Research for IPF and Other Forms of ILD
  • Resources
    • Aspirational Patient Journey
      • Aspirational Patient Journey
    • Basics of ILDs
    • Basics of IPF
    • Blog
    • Genetics of Familial Idiopathic Interstitial Pneumonia
    • IPF Patient Journey
      • Early Symptoms
      • Delayed Diagnosis
      • IPF Diagnosis
      • Pharmacologic Treatments
      • Making Sense of the Illness
      • Oxygen Therapy
      • Pulmonary Rehabilitation
      • Acute Exacerbations
      • Lifestyle Changes
      • Palliative Care
      • Hospice Care
      • Lung Transplant
    • IPF and PF-ILD Clinical Trials
    • Monitoring Disease Progression in Idiopathic Pulmonary Fibrosis
    • Patient Symposium
    • Peer To Peer Support
    • Phase IV IPF Clinical Trials
    • Pulmonary Function Testing
    • Starting Oxygen Therapy
    • Support Groups
    • Webinars
  • Clinical Trials
    • PCRC Patient Registry
    • BMS-986278-IPF
    • BMS-986278-PPF
    • Bexotegrast-IPF
    • DWN12088-IPF
    • EFZO-FIT
    • FIBRONEER-IPF
    • FIBRONEER-PF-ILD
    • Inhaled Treprostinil Clinical Trial
    • PRECISIONS Trial
  • Home
  • Contact
  • Support
  • Events
  • Tai Chi
  • ILD Centers in the USA
  • Pulmonary Rehab Programs
  • Search
  • Login

You are here

  1. Home ›
  2. COVID-19 ›

Phase 3 Trial Data for the FDA-Approved COVID-19 Vaccines

 
 Phase 3 Trial Data for the FDA-Approved COVID-19 Vaccines

Below are links to more information about Phase 3 trials of the COVID-19 that are approved for use in the United States either with a full approval or an Emergency Use Authorization.

Phase 3 Trial Data for the Pfizer-BioNTech COVID-19 Vaccine

Phase 3 Trial Data for the Moderna COVID-19 Vaccine

Phase 3 Trial Data for the Johnson & Johnson COVID-19 Vaccine

  • Home
  • Contact
  • Support
  • Events
  • Tai Chi
  • ILD Centers in the USA
  • Pulmonary Rehab Programs
  • Search
  • Login
  • About
  • Partner Centers
  • People
  • Project ECHO for ILD
  • Virtual Meetings
  • Resources
  • Clinical Trials

SUBSCRIBE TO OUR MAILING LISTS

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Copyright © 2024 Pulmonary Care and Research Collaborative, Ltd. 
Privacy Policy | Terms of Use



  • Kazançlı bir başlangıç yapmak için deneme bonusu sunan bu siteye göz atabilirsiniz.
  • Fırsatlarla dolu deneme bonusu veren siteler arasında öne çıkan bir seçenek burada.
  • Yeni üyeler için özel bonus veren siteler, avantajlı teklifleriyle dikkat çekiyor.
  • Kullanıcı memnuniyetine odaklanan bonus veren siteler, eşsiz fırsatlar sunuyor.
  • Güvenilir bir deneyim için deneme bonusu veren siteler, kazanç kapınızı aralıyor.
  • Hızlı kazanç fırsatı sağlayan deneme bonusu seçeneklerini keşfedin.
  • Avantajlı teklifleriyle deneme bonusu veren siteler, yüksek kazanç imkanı sunuyor.